Related Experiment Videos
Prophylactic implantable cardioverter defibrillator therapy in high-risk patients with coronary artery disease
1Arrhythmia and Pacemaker Service, University of Medicine and Dentistry, New Jersey Medical School.
Insights
Sudden cardiac death remains a risk for heart disease patients. Clinical trials are evaluating if implantable cardioverter defibrillators (ICDs) or drugs best prevent these events and improve survival.
Area of Science:
- Cardiology
- Electrophysiology
- Preventive Medicine
Background:
- Significant long-term mortality from sudden cardiac death persists in patients with ischemic heart disease and congestive heart failure.
- Risk stratification tools help identify high-risk individuals for arrhythmic events.
- Pharmacologic agents like beta-blockers and amiodarone show efficacy in primary prevention for specific populations.
Purpose of the Study:
- To review ongoing clinical trials investigating prophylactic antiarrhythmic interventions for sudden cardiac death.
- To compare the effectiveness of implantable cardioverter defibrillators (ICDs) versus pharmacologic therapy.
- To determine optimal treatment strategies for reducing mortality in high-risk cardiac patients.
Main Methods:
- Review of ongoing controlled clinical trials.
- Analysis of data comparing drug therapy, ICDs, or combined approaches.
- Evaluation of risk stratification predictors for arrhythmic events.
Main Results:
- Implantable cardioverter defibrillators (ICDs) have demonstrated significant reductions in sudden death rates in patients with a history of cardiac arrest.
- Ongoing trials are designed to provide definitive answers on prophylactic antiarrhythmic interventions.
- The superiority of device therapy over pharmacologic treatment is under investigation.
Conclusions:
- Despite advances, sudden cardiac death remains a critical concern in heart disease management.
- Prophylactic implantation of ICDs is a potential strategy for high-risk patients.
- Ongoing clinical trials are crucial for establishing evidence-based treatment guidelines for preventing sudden cardiac death.
Abstract:
Despite substantial progress in the management of ischemic heart disease and congestive heart failure, long-term mortality rates as a result of sudden cardiac death in such patients remain significant. Risk stratification that uses a combination of several predictors of clinical outcome has improved our ability to identify persons at high risk for future arrhythmic events. beta-Blockers and amiodarone are effective in primary prevention of sudden death in selected populations. In view of the impressive reduction in sudden death rates by implantable cardioverter defibrillators (ICDs) in patients with a history of cardiac arrest, prophylactic implantation may also be beneficial. The best way to treat these patients is not known. Three ongoing controlled clinical trials have been designed for drugs, ICDs, or both and will provide answers about whether prophylactic antiarrhythmic intervention with ICDs improves survival and whether device therapy is superior to pharmacologic treatment. Brief reports on these clinical trials are discussed in this review.